Genetic results may provide valuable insight into how you respond to certain medicines. Learn more about the new results the biobank may return to you.
The Biobank is beginning to return some genetic results to eligible participants who have signed the appropriate consent form and provided a blood sample that has been processed.
We completed the second round of our COVID-19 survey. Over 25,000 of you responded – thank you! The information that so many of you shared may help researchers and public health workers understand the impacts of the pandemic and why some groups are more affected than others.
Researchers at the University of Colorado Anschutz Medical Campus are looking for interested adults 60+ to participate in a research study to look at how inflammation influences memory and thinking.
In response to the COVID-19 pandemic, researchers from all over the globe came together to develop the COVID-19 Human Genetics Initiative, a massive group effort to help understand what (if any) genetic variants underlie who contracts COVID-19 and if any of those same variants can help predict who develops severe outcomes such as inpatient treatment.
We are excited to inform you that the CCPM biobank is collaborating with a company called BC Platforms to support research and discovery, and facilitate new drug development. We are joining BC Platforms’ “Global Data Partner Network”
Like most things in genetics, our work is done in partnership with many other groups across the country, or, indeed, around the world. Often this results in much more powerful analyses than we can do on our own and importantly, we have methods to collaborate securely and preserve privacy.
On March 26, 2020, the CCPM Biobank Laboratory launched a clinical diagnostic test for COVID-19. This test, in combination with other validated clinical tests on the Anschutz Medical Campus, is used by healthcare providers to determine what treatment patients should receive and whether isolation and quarantine are required.
We are very excited to inform you of a new partnership between the CCPM Biobank and Regeneron Genetics Center (RGC), a subsidiary of Regeneron Pharmaceuticals. CCPM and RGC will collaborate to create a large-scale genomics database comprising genetic data on approximately 450,000 samples for discovery research and to support patient care at UCHealth.
We are seeking 8-10 volunteers from the Biobank to help us improve the information that we provide to our participants at the time of enrollment, and as we begin to return genetic results.
The Biobank Clinical Operations team works on all operational aspects of patient recruitment, sample collection, patient and provider education, and coordination of activities between UCHealth and the Colorado Center for Personalized Medicine (CCPM) Biobank.